Apabetalone is under clinical development by Resverlogix and currently in Phase III for Cardiovascular Risk Factors. According to GlobalData, Phase III drugs for Cardiovascular Risk Factors have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Apabetalone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Apabetalone (RVX-208) is under development for the treatment of coronary artery disease, rheumatoid arthritis, peripheral artery disease, chronic kidney disease, retinal degeneration, pulmonary arterial hypertension, vascular cognitive dementia, complement mediated disease, and coronavirus disease 2019 (COVID-19). It is administered orally. It targets the BD2 domain of the BRD4 (bromodomain-containing protein 4) belonging to the BET (bromodomain and extra-terminal domain) family. The drug candidate is developed based on the company’s proprietary NexVas platform. It was also under development for the treatment of dyslipidemia and Alzheimer’s disease, rheumatoid arthritis, pre-diabetes mellitus and paroxysmal nocturnal hemoglobinuria.
It was under development for the treatment for fabry disease, vascular dementias, facioscapulohumeral muscular dystrophy (FSHD), human immunodeficiency virus infections, malignant peripheral nerve sheath tumors (MPNST) and cognitive disorders.
Resverlogix is a biotechnology company which develops small molecule therapeutics for cardiovascular disease, diabetes mellitus, and chronic kidney disease. The company’s lead product candidate include Apabetalone (RVX-208) is a first-in-class small molecule that inhibits BET bromodomain proteins for the treatment of high-risk cardiovascular disease patients with type 2 diabetes mellitus and low high-density lipoprotein (HDL), and Alzheimer’s disease. Resverlogix utilizes an epigenetics drug development platform, BET technology that targets BET proteins and identify small molecule candidates that specifically bind to BET bromodomains and regulate gene expression, among others. It also discovers and develops therapeutics for neurodegenerative diseases, peripheral artery disease and rare orphan diseases. The company operates through its representative office located in San Francisco, California, the US. Resverlogix is headquartered in Calgary, Alberta, Canada.
For a complete picture of Apabetalone’s drug-specific PTSR and LoA scores, buy the report here.